995861

Among patients with atrial high-rate episodes detected by implantable devices, anticoagulation with edoxaban did not show a benefit but did increase bleeding risk in the NOAH-AFNET 6 trial.

Related Keywords

Canada ,United Kingdom ,Amsterdam ,Noord Holland ,Netherlands ,Hamburg ,Germany ,Indiana ,United States ,German ,Stuart Connolly ,Paulus Kirchhof ,Barbara Casadei ,Daiichi Sankyo Europe ,Mcmaster University ,Cardiovascular Research ,American College Of Cardiology Ed Fry ,Implications For Wearable Technology ,University Heart ,Vascular Center Hamburg ,Vincent Heart Center ,University Of Hamburg ,German Center ,European Society Of Cardiology ,European Society ,New England Journal ,Medscape Cardiology ,John Radcliffe Hospital ,American College ,Cardiology Ed Fry ,Ascension Indiana ,Daiichi Sankyo ,Presented August ,Atrial Fibrillation ,F Atrial Fibrillation ,Anticoagulation Therapy ,Anticoagulant ,Anticoagulation ,Thromboembolism ,Stroke ,Erebrovascular Accident ,Va Cerebrovascular Accident ,Cardiometabolic Risk ,Arrhythmia ,Stroke Risk ,Europe ,European ,Heart ,Hemorrhage ,Bleeding ,Atrial Tachycardia ,Embolism ,Paroxysmal Supraventricular Tachycardia ,Supraventricular Tachycardia ,Vt Supraventricular Tachycar ,